Viatris (VTRS)
(Delayed Data from NSDQ)
$11.35 USD
-0.21 (-1.82%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $11.34 -0.01 (-0.09%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth D Momentum B VGM
Viatris (VTRS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$12.83 | $15.00 | $11.00 | 10.99% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Viatris comes to $12.83. The forecasts range from a low of $11.00 to a high of $15.00. The average price target represents an increase of 10.99% from the last closing price of $11.56.
Analyst Price Targets (6 )
Broker Rating
Viatris currently has an average brokerage recommendation (ABR) of 3.14 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 3.50 a month ago based on six recommendations.
Of the seven recommendations deriving the current ABR, one is Strong Buy, representing 14.29% of all recommendations. There was no Strong Buy or Buy recommendation a month ago.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 0 | 0 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 4 | 4 | 4 | 4 | 4 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 3.14 | 3.14 | 3.50 | 3.50 | 3.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/23/2024 | Piper Sandler | David Amsellem | Hold | Hold |
7/19/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
2/29/2024 | Not Identified | Not Identified | Strong Sell | Strong Sell |
12/29/2023 | Goldman Sachs | Nathan Rich | Hold | Hold |
10/20/2023 | UBS | Ashwani Verma | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.14 |
ABR (Last week) | 3.14 |
# of Recs in ABR | 7 |
Average Target Price | $12.83 |
LT Growth Rate | NA |
Industry | Medical Services |
Industry Rank by ABR | 150 of 253 |
Current Quarter EPS Est: | 0.68 |